JP2018522887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522887A5 JP2018522887A5 JP2018501155A JP2018501155A JP2018522887A5 JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5 JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hpv
- subject
- antibody according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701806 Human papillomavirus Species 0.000 claims 8
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000006311 Cyclin D1 Human genes 0.000 claims 1
- 108010058546 Cyclin D1 Proteins 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000012303 cytoplasmic staining Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 238000012758 nuclear staining Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169277A JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192396P | 2015-07-14 | 2015-07-14 | |
| US62/192,396 | 2015-07-14 | ||
| PCT/US2016/042297 WO2017011666A1 (en) | 2015-07-14 | 2016-07-14 | Method of treating cancer using immune checkpoint inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Division JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522887A JP2018522887A (ja) | 2018-08-16 |
| JP2018522887A5 true JP2018522887A5 (enExample) | 2019-08-22 |
Family
ID=56551000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501155A Withdrawn JP2018522887A (ja) | 2015-07-14 | 2016-07-14 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10544224B2 (enExample) |
| EP (2) | EP3858859B1 (enExample) |
| JP (3) | JP2018522887A (enExample) |
| KR (2) | KR20180027576A (enExample) |
| CN (1) | CN107922502A (enExample) |
| CY (1) | CY1123993T1 (enExample) |
| DK (2) | DK3322731T3 (enExample) |
| ES (1) | ES2855798T3 (enExample) |
| FI (1) | FI3858859T3 (enExample) |
| HR (1) | HRP20210399T1 (enExample) |
| HU (1) | HUE053966T2 (enExample) |
| LT (1) | LT3322731T (enExample) |
| PL (1) | PL3322731T3 (enExample) |
| PT (1) | PT3322731T (enExample) |
| RS (1) | RS61532B1 (enExample) |
| SI (1) | SI3322731T1 (enExample) |
| SM (1) | SMT202100131T1 (enExample) |
| WO (1) | WO2017011666A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016149201A2 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| WO2017004079A1 (en) | 2015-06-29 | 2017-01-05 | Biomed Valley Discoveries, Inc. | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment |
| BR112018000768A2 (pt) | 2015-07-13 | 2018-09-25 | Cytomx Therapeutics Inc | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos |
| SMT202100131T1 (it) | 2015-07-14 | 2021-05-07 | Bristol Myers Squibb Co | Metodo di trattamento di un cancro usando un inibitore di checkpoint immunitari; anticorpo che si lega al recettore della morte programmata-1 (pd-1) o al ligando della morte programmata 1 (pd-l1) |
| AU2016305697B2 (en) | 2015-08-11 | 2023-02-02 | WuXi Biologics Ireland Limited | Novel anti-PD-1 antibodies |
| CN107949573B (zh) | 2015-09-01 | 2022-05-03 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| PT3377534T (pt) * | 2015-11-18 | 2025-07-10 | Bristol Myers Squibb Co | Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4 |
| CA3007421A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
| WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
| CN109715173A (zh) * | 2016-07-15 | 2019-05-03 | 维拉克塔治疗公司 | 供基于nk细胞的疗法使用的hdac抑制剂 |
| MX2019003755A (es) * | 2016-10-06 | 2019-08-12 | Pfizer | Regimen de dosificacion de avelumab para el tratamiento de cancer. |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| IL266918B2 (en) | 2016-12-07 | 2024-03-01 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| WO2018226529A1 (en) * | 2017-06-05 | 2018-12-13 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
| MY201935A (en) * | 2018-01-12 | 2024-03-25 | Grail Inc | Methods for analyzing viral nucleic acid |
| MA51844A (fr) * | 2018-02-13 | 2021-05-19 | Merck Sharp & Dohme | Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4 |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| EP3774911A1 (en) * | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP3801501A4 (en) * | 2018-06-06 | 2022-03-23 | The Regents of the University of California | ESTROGEN RECEPTOR INHIBITORS AND THEIR USES |
| US20210255168A1 (en) * | 2018-06-13 | 2021-08-19 | King Faisal Specialist Hospital & Research Centre | A method of precision cancer therapy |
| EP3873527A4 (en) * | 2018-10-31 | 2022-09-07 | Genentech, Inc. | METHOD AND MEDICATION FOR THE TREATMENT OF CANCERS NOT RESPONDING TO A PD-1/PD-L1 SIGNALING INHIBITOR |
| CN113365659B (zh) * | 2019-01-31 | 2023-08-18 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| TW202138006A (zh) * | 2019-12-13 | 2021-10-16 | 韓商三星Ｂｉｏｅｐｉｓ股份有限公司 | 穩定之抗-pd1抗體醫藥調配物 |
| BR112022012081A2 (pt) * | 2019-12-20 | 2022-08-30 | Merck Sharp & Dohme Llc | Método para tratar câncer, kit, e, uso de uma combinação terapêutica |
| KR102541413B1 (ko) | 2020-02-06 | 2023-06-12 | 영남대학교 산학협력단 | 면역 체크포인트 억제제 및 ampk 활성화제를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 |
| KR102779377B1 (ko) | 2022-07-22 | 2025-03-12 | 가톨릭대학교 산학협력단 | 디옥시시코닌 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| KR102893442B1 (ko) * | 2022-12-23 | 2025-12-01 | 가톨릭대학교 산학협력단 | 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| WO1998045331A2 (en) | 1997-04-07 | 1998-10-15 | Genentech, Inc. | Anti-vegf antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP1151002A4 (en) | 1999-01-29 | 2002-05-02 | Imclone Systems Inc | KDR-SPECIFIC ANTIBODIES AND USES THEREOF |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| ATE475431T1 (de) | 2002-03-04 | 2010-08-15 | Imclone Llc | Kdr-spezifische humane antikörper und deren anwendung |
| EP1537878B1 (en) | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| CN102397542B (zh) | 2004-11-18 | 2014-05-07 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907000T4 (da) * | 2005-06-08 | 2020-03-30 | The President And Fellows Of Harvard College | Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1). |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| KR101502267B1 (ko) | 2007-11-09 | 2015-03-18 | 페레그린 파마수티컬즈, 인크 | 항-ｖｅｇｆ 항체 조성물 및 방법 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EA023148B1 (ru) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Композиции на основе антагонистов pd-1 и их применение |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| AU2013327116C1 (en) | 2012-10-02 | 2018-08-30 | Bristol-Myers Squibb Company | Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer |
| RS63571B9 (sr) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva |
| EP3508502B1 (en) * | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JP2017517525A (ja) | 2014-05-29 | 2017-06-29 | メディミューン リミテッド | Ｈｐｖ陰性がんの治療のためのｐｄｌ−１およびｐｄ−１のアンタゴニスト |
| US10354541B2 (en) | 2014-07-02 | 2019-07-16 | Raytheon Bbn Technologies Corporation | Tutor model building system |
| MA40344A (fr) * | 2014-07-18 | 2016-01-21 | Advaxis Inc | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer |
| EP3183269A2 (en) * | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| KR20250004095A (ko) * | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| SMT202100131T1 (it) | 2015-07-14 | 2021-05-07 | Bristol Myers Squibb Co | Metodo di trattamento di un cancro usando un inibitore di checkpoint immunitari; anticorpo che si lega al recettore della morte programmata-1 (pd-1) o al ligando della morte programmata 1 (pd-l1) |
-
2016
- 2016-07-14 SM SM20210131T patent/SMT202100131T1/it unknown
- 2016-07-14 DK DK16744626.9T patent/DK3322731T3/da active
- 2016-07-14 DK DK20214749.2T patent/DK3858859T3/da active
- 2016-07-14 KR KR1020187003984A patent/KR20180027576A/ko not_active Ceased
- 2016-07-14 EP EP20214749.2A patent/EP3858859B1/en active Active
- 2016-07-14 SI SI201631090T patent/SI3322731T1/sl unknown
- 2016-07-14 WO PCT/US2016/042297 patent/WO2017011666A1/en not_active Ceased
- 2016-07-14 PL PL16744626T patent/PL3322731T3/pl unknown
- 2016-07-14 LT LTEP16744626.9T patent/LT3322731T/lt unknown
- 2016-07-14 KR KR1020257014642A patent/KR20250065936A/ko active Pending
- 2016-07-14 HU HUE16744626A patent/HUE053966T2/hu unknown
- 2016-07-14 ES ES16744626T patent/ES2855798T3/es active Active
- 2016-07-14 PT PT167446269T patent/PT3322731T/pt unknown
- 2016-07-14 CN CN201680052756.8A patent/CN107922502A/zh active Pending
- 2016-07-14 RS RS20210284A patent/RS61532B1/sr unknown
- 2016-07-14 US US15/210,612 patent/US10544224B2/en active Active
- 2016-07-14 HR HRP20210399TT patent/HRP20210399T1/hr unknown
- 2016-07-14 JP JP2018501155A patent/JP2018522887A/ja not_active Withdrawn
- 2016-07-14 FI FIEP20214749.2T patent/FI3858859T3/fi active
- 2016-07-14 EP EP16744626.9A patent/EP3322731B1/en active Active
-
2019
- 2019-12-05 US US16/704,913 patent/US20200190198A1/en not_active Abandoned
-
2021
- 2021-03-26 CY CY20211100264T patent/CY1123993T1/el unknown
-
2022
- 2022-10-21 JP JP2022169277A patent/JP2023024973A/ja active Pending
-
2023
- 2023-07-26 US US18/359,696 patent/US20240124592A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106098A patent/JP2025138726A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522887A5 (enExample) | ||
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| JP2018515474A5 (enExample) | ||
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| IL278423B1 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| JP2018500332A5 (enExample) | ||
| Vici et al. | Emerging biological treatments for uterine cervical carcinoma | |
| JP2016528195A5 (enExample) | ||
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| JP2019503387A5 (enExample) | ||
| JP2016525117A5 (enExample) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| JP2017534633A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| JP2017537090A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| WO2018112407A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| JP2019517504A5 (enExample) | ||
| JP2023525664A (ja) | がんの処置のためのアルファ－２アドレナリン作動性受容体アゴニスト | |
| MX2021004226A (es) | Terapia combinada contra el cáncer. | |
| WO2017177217A3 (en) | Chimeric receptors and uses thereof in immune therapy | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей |